Physicians' Academy for Cardiovascular Education

Careful implementation of PCSK9 inhibitors in clinical practice

Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

Promising results in pivotal trials of novel lipid-modifying drugs

Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John JP Kastelein, MD (AMC Amsterdam, The Netherlands)

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada
##SCROLLER_ITEMS_FULL_TITLE##

New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

Nov. 22, 2016 - Kausik Ray, MD - Imperial College London, United Kingdom
##SCROLLER_ITEMS_FULL_TITLE##

Brief update on various pharmacotherapeutic strategies to lower CV risk

Nov. 21, 2016 - AHA 2016 - Prof. Wouter Jukema, MD (LUMC Leiden, The Netherlands)
##SCROLLER_ITEMS_FULL_TITLE##

PCSK9 inhibitor on top of statin therapy gives additional atheroma volume regression

Nov. 21, 2016 - AHA 2016 - Steve Nissen, MD (Cleveland Clinic, Cleveland, OH, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?

Aug. 27, 2016 - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

PCSK9, the short track road from discovery as drug target towards the clinic

Aug. 27, 2016 - ESC 2016, Rome - Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France

Role of PCSK9 in the regulation of LDL cholesterol

Sep. 12, 2016

LDL cholesterol, the LDL receptor pathway & PCSK9

Sep. 10, 2016

The future perspectives for care for patients with high Lp(a)

May 27, 2016 - Innsbruck, Germany - Prof. Erik Stroes, MD PhD – Academic Medical Center, Amsterdam, The Netherlands - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands

Steps forward in lipid-lowering therapy

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Robert P. Giugliano, MD - Boston, MA, USA
##SCROLLER_ITEMS_FULL_TITLE##

GAUSS-3: Statin intolerance a real problem and PCSK9 inhibition with evolocumab effective

Apr. 3, 2016 - ACC 2016, Chicago - Steven L Nissen
##SCROLLER_ITEMS_FULL_TITLE##

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##SCROLLER_ITEMS_FULL_TITLE##

Impacting lipid disorders through personalised healthcare

Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##SCROLLER_ITEMS_FULL_TITLE##

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##SCROLLER_ITEMS_FULL_TITLE##

Lipid Management 2020: A glance at the future

Sep. 24, 2015
##SCROLLER_ITEMS_FULL_TITLE##

Patients confident to use injectable PCSK9-inhibitor via self-injection

May 25, 2015 - ISA2015, Amsterdam - Bertrand Cariou
##SCROLLER_ITEMS_FULL_TITLE##

CETP-inhibitor reduces non-HDL-c and PCSK9 in animal model

May 24, 2015 - ISA2015, Amsterdam - Dr. Yanan Wang
##SCROLLER_ITEMS_FULL_TITLE##

The effects of a PCSK9-inhibitor on various lipid fractions

May 24, 2015 - ISA2015, Amsterdam - Gisette Reyes-Soffer
##SCROLLER_ITEMS_FULL_TITLE##

Homozygous FH: treatment challenges

May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Frederick Raal
##SCROLLER_ITEMS_FULL_TITLE##

PCSK9-inhibitor less frequently administered may be effective treatment option

June 15, 2015 - ISA Amsterdam - Prof. Eli Roth
##SCROLLER_ITEMS_FULL_TITLE##

Large pooled analysis reveals no safety concerns with PCSK9-inhibitor

June 16, 2015 - ISA2015, Amsterdam - Jennifer Robinson
##SCROLLER_ITEMS_FULL_TITLE##

TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients

June 15, 2015 - ISA2015, Amsterdam - Prof. Frederick Raal
##SCROLLER_ITEMS_FULL_TITLE##

Lipids: Who is at real high risk?

May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
##SCROLLER_ITEMS_FULL_TITLE##

OSLER studies Compelling data on PCSK9 inhibition

Mar. 15, 2015 - ACC 2015, San Diego - Marc Sabatine, MD Boston
##SCROLLER_ITEMS_FULL_TITLE##

OSLER 1 & 2: Long term efficacy and safety outcomes PCSK9 inhibition

Mar. 16, 2015 - ACC 2015, San Diego - Prof.dr. John Kastelein

Anti-inflammatory changes in response to PCSK9 antibody treatment in monocytes of FH patients

Feb. 20, 2017 - Bernelot Moens SJ et al., - Eur Heart J 2017

Circulating monocytes of FH patients not on statins showed a pro-inflammatory phenotype and intracellular lipid accumulation, which was reversed upon treatment with PCSK9 antibodies.

Few adverse events of very low LDL-C levels with PCSK9 antibody

Feb. 8, 2017 - Robinson JG, et al. - J Am Coll Cardiol. 2017

In a meta-analysis with more than 5 000 patients with a median alirocumab exposure of 1.5 years, low levels of LDL-C (<25 mg/dl) were associated with an increased incidence of cataracts.

PCSK9 inhibitor increases the removal of LDL and Lp(a) from the circulation via LDL-receptors

Feb. 7, 2017 - Reyes-Soffer G et al. - Circulation. 2017

Alirocumab treatment of healthy volunteers reduced LDL-C and LDL-apoB concentrations and doubled the efficiency with which LDL particles were removed from the circulation.

PCSK9 inhibitor non-inferior to placebo for effect on cognitive function

Feb. 3, 2017 - news
Evolocumab FOURIER CV outcomes study lowers CV risk in high-risk patients. Simultaneously, a trial showed that the antibody against PCSK9 is non-inferior to placebo for the effect on cognitive function.

The evolocumab EBBINGHAUS trial showed that the antibody against PCSK9 is non-inferior to placebo for the effect on cognitive function.

PCSK9 inhibitor significantly reduced CV risk in ASCVD patients in FOURIER outcomes study

Feb. 3, 2017 - news
Evolocumab FOURIER CV outcomes study lowers CV risk in high-risk patients. Simultaneously, a trial showed that the antibody against PCSK9 is non-inferior to placebo for the effect on cognitive function.

Evolocumab CV outcomes study meets primary and key secondary endpoints, showing reduced risk of CV events in those with ASCVD already on optimised statin therapy.

Patients with heterozygous familial hypercholesterolemia benefit from PCSK9-antibody

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo with heterozygous familial hypercholesterolemia

Jan. 11, 2017 - Kastelein JJP, et al. - J Clin Lipidol, 2017

In four studies with patients with heterozygous familial hypercholesterolemia, alirocumab resulted in significant LDL-C-lowering and was well tolerated.

siRNAs with promising therapeutic potential

Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs

Jan. 10, 2017 - Khvorova A. - N Engl J Med 2017

siRNAs, such as inclisiran that targets PCSK9, are specific, stable and relatively simple to manufacture and show promising LDL-c-lowering efficacy in a phase 3 trial.

Careful implementation of PCSK9 inhibitors in clinical practice

Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)
Implementation of PCSK9 inhibition in clinical practice before the outcome data

CSI Rome Terje Pedersen defended the 'contra'-argument in a discussion on the use of PCSK9 inhibitors in current clinical practice. He explains to Lotte Koopal and Gijs Berkelmans that while being involved in clinical studies of a PCSK9 antibody, he is still comfortable in the contra-position.

Promising results in pivotal trials of novel lipid-modifying drugs

Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John JP Kastelein, MD (AMC Amsterdam, The Netherlands)

AHA 2016 Prof. John JP Kastelein, MD summarises the promising results of the pivotal GLAGOV and ORION-1 trials, presented at the AHA 2016. In GLAGOV, atheroma regression was seen with evolocumab treatment, and in ORION-1 RNA-interference directed against PCSK9 yielded durable LDL-c lowering effect.

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada
Epigenetic apabetalone or RVX-208 that alters chromatin structure and gene activity gave clinical benefit in phase 2 study.

AHA 2016 The orally active epigenetic drug RVX-208 or apabetalone that alters gene activity by modifying chromatin structure, lowered the incidence of MACE in a phase 2b study. This effect could not entirely be attributed to an effect on HDL, explains dr. Norman Wong.

PCSK9 and HMGCR genetic variants are associated to risk of type 2 diabetes

Dec. 7, 2016 - Ference et al., NEJM and Schmidt et al., Lancet Diabetes Endocrinol

Two recent studies describe genetic variants of PCSK9 and HMGCR resulting in low LDL-c levels, thereby mimicking PCSK9/statin therapy, and are associated with increased risk of diabetes.

PCSK9 and HMGCR genetic variants are associated with risk of type 2 diabetes

Dec. 6, 2016

Two recent studies describe genetic variants of PCSK9 and HMGCR resulting in low LDL-c levels, thereby mimicking PCSK9/statin therapy, and are associated with increased risk of diabetes. 

3' education

Promising results in pivotal trials of novel lipid-modifying drugs

Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John JP Kastelein, MD (AMC Amsterdam, The Netherlands)

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada

New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

Nov. 22, 2016 - Kausik Ray, MD - Imperial College London, United Kingdom
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Brief update on various pharmacotherapeutic strategies to lower CV risk

Nov. 21, 2016 - AHA 2016 - Prof. Wouter Jukema, MD (LUMC Leiden, The Netherlands)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

PCSK9 inhibitor on top of statin therapy gives additional atheroma volume regression

Nov. 21, 2016 - AHA 2016 - Steve Nissen, MD (Cleveland Clinic, Cleveland, OH, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Steps forward in lipid-lowering therapy

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Robert P. Giugliano, MD - Boston, MA, USA

GAUSS-3: Statin intolerance a real problem and PCSK9 inhibition with evolocumab effective

Apr. 3, 2016 - ACC 2016, Chicago - Steven L Nissen
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Impacting lipid disorders through personalised healthcare

Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Patients confident to use injectable PCSK9-inhibitor via self-injection

May 25, 2015 - ISA2015, Amsterdam - Bertrand Cariou
##RIGHT_SECTION_ITEMS_FULL_TITLE##

CETP-inhibitor reduces non-HDL-c and PCSK9 in animal model

May 24, 2015 - ISA2015, Amsterdam - Dr. Yanan Wang
##RIGHT_SECTION_ITEMS_FULL_TITLE##

The effects of a PCSK9-inhibitor on various lipid fractions

May 24, 2015 - ISA2015, Amsterdam - Gisette Reyes-Soffer
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Homozygous FH: treatment challenges

May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Frederick Raal
##RIGHT_SECTION_ITEMS_FULL_TITLE##

PCSK9-inhibitor less frequently administered may be effective treatment option

June 15, 2015 - ISA Amsterdam - Prof. Eli Roth
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Large pooled analysis reveals no safety concerns with PCSK9-inhibitor

June 16, 2015 - ISA2015, Amsterdam - Jennifer Robinson
##RIGHT_SECTION_ITEMS_FULL_TITLE##

TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients

June 15, 2015 - ISA2015, Amsterdam - Prof. Frederick Raal
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Lipids: Who is at real high risk?

May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
##RIGHT_SECTION_ITEMS_FULL_TITLE##

OSLER studies Compelling data on PCSK9 inhibition

Mar. 15, 2015 - ACC 2015, San Diego - Marc Sabatine, MD Boston
##RIGHT_SECTION_ITEMS_FULL_TITLE##

OSLER 1 & 2: Long term efficacy and safety outcomes PCSK9 inhibition

Mar. 16, 2015 - ACC 2015, San Diego - Prof.dr. John Kastelein
##RIGHT_SECTION_ITEMS_FULL_TITLE##

2014: the major lipid developments in review

Dec. 20, 2014 - Amsterdam - Prof. John JP Kastelein
##RIGHT_SECTION_ITEMS_FULL_TITLE##

IMPROVE-IT: Implications for clinical practice & guidelines

Nov. 19, 2014 - Chicago, Il, USA - Prof. Kausik Ray
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Confirmation LDL-c lowering beyond current borders with non statin therapy is effective

Nov. 19, 2014 - Chicago, Il, USA - Prof Erik Stroes
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Potential role of PCSK9 inhibitors

Nov. 26, 2014 - VBWG Chicago - Michael J Koren
##RIGHT_SECTION_ITEMS_FULL_TITLE##

PCSK9 inhibition: Clinical Update 2014

Oct. 29, 2014 - Snapshot 2014 - Dr Evan Stein
##RIGHT_SECTION_ITEMS_FULL_TITLE##

HoFH: New insights in prevalence and therapy

Oct. 26, 2014 - Snapshot 2014 - dr Kees Hovingh
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Is inflammation reduction key for targeting residual risk, beyond lowering LDL-c?

Oct. 18, 2014 - Snapshot 2014 - Prof. Paul M Ridker, MD
##RIGHT_SECTION_ITEMS_FULL_TITLE##

IMPROVE-IT: Scenarios for understanding the results

Sep. 9, 2014 - Barcelona - Prof Chris Packard
##RIGHT_SECTION_ITEMS_FULL_TITLE##

LDL cholesterol, LDL receptor & PCSK9

July 31, 2013
##RIGHT_SECTION_ITEMS_FULL_TITLE##

LDL Receptor Function and Life Cycle

Dec. 27, 2013
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Targeting fasting and post-prandial triglycerides

Sep. 1, 2013 - Snapshot 2013 - Dr. Joanne M. Donovan
##RIGHT_SECTION_ITEMS_FULL_TITLE##

PCSK9 & LDL- The best story of translational medicine?

Sep. 8, 2013 - Amsterdam, August 31, 2013 - Dr Evan Stein
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Treating the untreatable high LDL-c

June 17, 2013 - Kuala Lumpur - Dato' dr Khoo Kah Lin
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Antibodies against PCSK9: A new LDL-c lowering therapy?

Mar. 31, 2013 - CVC 2013 - Dr. Kees Hovingh, Amsterdam
##RIGHT_SECTION_ITEMS_FULL_TITLE##

10' education

Careful implementation of PCSK9 inhibitors in clinical practice

Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?

Aug. 27, 2016 - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

PCSK9, the short track road from discovery as drug target towards the clinic

Aug. 27, 2016 - ESC 2016, Rome - Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France

The future perspectives for care for patients with high Lp(a)

May 27, 2016 - Innsbruck, Germany - Prof. Erik Stroes, MD PhD – Academic Medical Center, Amsterdam, The Netherlands - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Lipid Management 2020: A glance at the future

Sep. 24, 2015
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Critique on the new AHA / ACC guidelines for lipid management

Nov. 7, 2014 - Barcelona, ESC - Prof Kausik Ray, Imperial College London, United KIngdom
##RIGHT_SECTION_ITEMS_FULL_TITLE##

HoFH: New insights and expanding therapeutic options

Sep. 6, 2014 - Snapshot 2014 - Dr. Kees Hovingh, AMC, Amsterdam, The Netherlands
##RIGHT_SECTION_ITEMS_FULL_TITLE##

PCSK9 inhibition: Novel insights into a new therapeutic approach for the lowering of LDL-C: the PCSK9 saga

Sep. 3, 2014
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Biology and validation of PCSK9 as a novel target to lower LDL-C

Aug. 30, 2014 - Barcelona, ESC - Prof. John JP Kastelein
##RIGHT_SECTION_ITEMS_FULL_TITLE##

PCSK9: The promise of a new target in lipid management

Sep. 3, 2014 - Barcelona, ESC - Prof. John E Deanfield, UCL, London
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Emerging therapies to lower LDL-cholesterol

May 8, 2014
##RIGHT_SECTION_ITEMS_FULL_TITLE##

PCSK9: the new lipid target in preventive cardiology?

Sep. 26, 2013

The roadmap of PCSK9 inhibitors towards the clinic

Sep. 30, 2013
##RIGHT_SECTION_ITEMS_FULL_TITLE##

PCSK9 inhibition: Mechanistic insights into a new therapeutic approach for the lowering of LDL-c

Sep. 30, 2013
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Monoclonal antibodies that target PCSK9: What the first clinical trial data are telling?

Sep. 30, 2013
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Familial Hypercholesterolemia: Why are we not reaching goals in these patients?

Sep. 30, 2013
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Lowering of LDL-C: Novel concepts and novel promises

Sep. 14, 2013
##RIGHT_SECTION_ITEMS_FULL_TITLE##